Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 08, 2005. The report serves as a notification of transactions involving directors, specifically detailing changes in interests in American Depositary Shares (ADSs) by Dr. T Yamada.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a disclosure of insider trading activity and does not contain consolidated financial statements.
Material Changes
The material change reported is the exercise of share options by Director Dr. T Yamada:
- Option Exercise: 74,868 ADSs granted on March 25, 1996, were exercised at a price of $22.36494 per ADS.
- Tranche 1: 16,400 ADSs sold on December 6, 2005, at an average price of $50.52 per share.
- Tranche 2: 58,468 ADSs sold on December 7, 2005, at an average price of $50.1035 per share.
- Resulting Holding: Dr. Yamada's total shareholding remains at 72,805 ADSs.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business performance, or discussion of risks and contingencies. It notes that Dr. Yamada's shareholding exceeds the company's requirement for executive directors to hold shares valued at three times their annual base salary, as his current holding is equivalent to more than four and a half times his base salary.
Investor Verification Points
- Verify the current market price of GSK ADSs to assess the realized gain from the option exercise price ($22.36) versus the sale prices (~$50.10-$50.52).
- Confirm Dr. Yamada's continued compliance with the company's share ownership policy (holding >3x base salary).
- Review the SmithKline Beecham US 1991 Share Option Plan terms regarding the lapse date of March 25, 2006.